Senseonics effectively ceased operations, per an 8-K filed on Thursday. The Company is, effective immediately, suspending commercial sales in the United States of its 90-day Eversense continuous glucose monitoring (“CGM”) system to new patients and physician practices. The company stated that it intends to continue distributing the 90-day Eversense system to patients currently using the system for the foreseeable future.